Special Issue

Vaccine Hesitancy and Child Immunizations: Rationales, Issues and Knowledge Gaps 2022

Message from the Guest Editor

Globally, infant and childhood vaccine coverage rates are still not high enough, with outbreaks of vaccinepreventable diseases occurring frequently, even in highincome countries. Vaccine hesitancy is one of the factors explaining suboptimal percentages of vaccination coverage, which is defined by the SAGE group as a "delay in acceptance or refusal of vaccines" despite availability of vaccine services". The decision not to vaccinate or to delay vaccine shots is derived from a complex decision-making process influenced by numerous factors related to population, context, environment, historical period and single vaccines. This Special Issue focuses on the current knowledge and strategies that may be used to reduce vaccine hesitancy and improve vaccination coverage rates in infant and childhood groups. The submission of original articles, systematic reviews, short communications and other work on related topics is welcome. Manuscripts will undergo standard journal peer-review practices, and those accepted for publication will appear in the Special Issue "Vaccine Hesitancy and Child Immunizations: Rationales, Issues and Knowledge Gaps".

Guest Editor

Dr. Davide Gori

Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy

Deadline for manuscript submissions

closed (15 September 2022)



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/112553

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

